Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention B.V

Drug Profile

Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention B.V

Alternative Names: Ad26 Mos HIV; Ad26 Mos HIV + clade C gp140; Ad26 mosaic vector + gp140; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos.HIV + gp140; Adenovirus-serotype-26-Mosaic-HIV-vaccine; Adenovirus-serotype-26-Mosaic-HIV-vaccine + Clade C glycoprotein 140; HIV Px Vaccine; JNJ-9220

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; International AIDS Vaccine Initiative; Janssen Vaccines and Prevention B.V; Johnson & Johnson; U.S. Military HIV Research Program
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 07 Sep 2022 (Phase-III development is ongoing in USA and Europe (Johnson & Johnson pipeline, September 2022)
  • 25 Apr 2022 Janssen Vaccines and Prevention B.V completes a phase-II clinical trial in HIV infections (Prevention) in USA (IM) (NCT02788045)
  • 01 Mar 2022 Janssen Vaccines & Prevention B.V. completes a phase-I/II clinical trials in HIV infections (Prevention) in USA, Uganda, Thailand, South Africa, Rwanda (IM) (NCT02315703)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top